Theme: Care about Gastrointestinal cancer for healthy lifestyle

GI Cancer 2016

GI Cancer 2016

Conferenceseries LLC  invites all the participants across the globe to attend ‘International Conference on Gastrointestinal Cancer and Therapeutics’ during September 26-27, 2016 at Toronto, Canada which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Conference Series LLC, the host of this conference is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe

Gastrointestinal Cancer 2016 provide you the best opportunity to reach the largest assemblage of participants from the cancer meeting, oncology society, European oncology conferences, surgical oncology, global cancer conference to Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition of your research work. World-renowned speakers, the most recent techniques, developments, the newest updates and advancements in Pancreatic cancer, Colorectal Cancer, Liver cancer, Stomach cancer, Esophageal cancer, and Gall bladder cancer   are hallmarks of this event.

Our cancer conferences also provides members and participants from major societies like American oncology society, European Society for Medical Oncology, Canadian cancer society, Colorectal Cancer Association of Canada – CCAC.

Gastrointestinal Cancer 2016 will mainly focus on the Cause of the cancer its Symptoms, Diagnosis, Treatment, Tests, Pathogenesis, Surgical and Non-Surgical Methods, Signs & Symptoms, Diagnosis, Chemotherapy ,Surgery and  Immunotherapy of Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Esophageal Cancer, Gastric Cancer, Gastrointestinal  Stromal Tumors, Gall Bladder Cancer, Oncology Nursing and Primary care, Imaging and Gastrointestinal Cancer, Cancer pharmacology.

Track 1: Colorectal Cancer

Colorectal cancer is a term for cancer that starts in either the colon or the rectum. Colon cancer and rectal cancer have many features in common. Colon cancer and cancer of the rectum can begin as a small polyp, detectable through regular cancer screening, such as colonoscopy. Colon cancer symptoms include a change in bowel habits like bleeding or blood in stools, but often there are no symptoms. With early detection, surgery, radiation, and/or chemotherapy can be effective treatment. Rectal cancer begins in the rectum. It’s also called colorectal cancer because it can occur above the rectum, in the colon or in the rectum. Some people are at higher risk because of a family history of certain genetic disorders such as Lynch syndrome. Colon cancer is a type of cancer that begins in the colon, an organ that is part of the large intestine and the body’s digestive system. Small intestine cancer, also known as small bowel cancer, begins in cells of the small intestine, the part of the digestive system located between the stomach and large intestine. It’s rare, affecting about 9,000 people a year in the United States.

Related Conferences:

Surgical Oncology Conference October  03-05, 2016 Atlanta, Georgia, USA. 14th World  Cancer Therapy Congress December  05-07, 2016 Philadelphia, Pennsylvania, USA.13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE.Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. Spring Colorectal Meeting New Zealand September 14 - 17, 2016. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:  Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 2: Pancreatic Cancer

Pancreatic cancer is a disease in which malignant (cancerous) cells form in the tissues of the pancreas. The pancreas is a gland located behind the stomach and in front of the spine. The pancreas produces digestive juices and hormones that regulate blood sugar. Cells called exocrine pancreas cells produce the digestive juices, while cells called endocrine pancreas cells produce the hormones. Pancreatic cancer begins when abnormal cells within the pancreas grow out of control and form a tumour. The majority of pancreatic cancers start in the exocrine cells. Your pancreas secretes enzymes that aid digestion and hormones that help regulate the metabolism of sugars. Pancreatic neuroendocrine tumours (pancreatic NETs or PNETs) account for less than 5% of all pancreatic tumours.  They may be benign or malignant and they tend to grow slower than exocrine tumours.  They develop from the abnormal growth of endocrine (hormone-producing) cells in the pancreas called islet cells.  This is why these tumours are sometimes referred to as “islet cell tumours”. Pancreatic cancer often has a poor prognosis, even when diagnosed early. Pancreatic cancer spreads rapidly and is seldom detected in its early stages, which is a major reason why it's a leading cause of cancer death. Signs and symptoms may not appear until pancreatic cancer is quite advanced and complete surgical removal isn't possible.

Related Conferences:s

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia.12th World Cancer Conference September 26-28, 2016 London, UK. Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA .7th International Conference and Expo on Molecular & Cancer Biomarkers September 15-16, 2016 Berlin, Germany. Conference on Leukemia and Bone Marrow Transplantation October 17-18, 2016. Rome,Italy. International Society Of University Colon And Rectal Surgeons (ISUCRS 2016) Mumbai, India,23rd - 25th September 2016. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City,Japan. 8th European Multidisciplinary Colorectal Cancer Congress 11 - 13 december 2016 RAI Amsterdam Netharland.15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours  29-1 September,2016 Utrecht, Netherlands. European Colorectal Congress 2016 November 29, 2016 - December 2, 2016,St.Gallen , Switzerland. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States. 4th International Controversies in Rectal Cancer Conference 14th – 15th  September 2016 ICENI Centre Colchester Hospital, Colchester, Essex C04 5JL U.K.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 3: Colorectal Cancer: Causes

Inflammatory bowel disease (IBD) involves chronic inflammation of all or part of our digestive tract. IBD mainly includes ulcerative colitis and Crohn's diseaseHNPCC occurs when only a small number of polyps are present or polyps are not present at all. Tumours in patients with HNPCC begin as adenomas and frequently transform to Familial adenomatous polyposis (FAP) it is characterized by the development of many tens to thousands of adenomas in the rectum. Adenomatous polyps are more likely than others to become cancerous. Precancerous conditions may develop into cancer and most commonly appear as clumps of cells (polyps) that extend from the wall of the colon.

Related Conferences:

Surgical Oncology Conference October  03-05, 2016 Atlanta, Georgia, USA. 14th World Congress on Cancer Therapy December  05-07, 2016 Philadelphia, Pennsylvania, USA.13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE.Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. Spring Colorectal Meeting New Zealand September 14 - 17, 2016. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:  Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track4: ColorectalCancer:Symptoms

Effects of colorectal cancer are:

·Rectal cancer causes rectal bleeding and blood in the stool, which may cause the stool to look dark in colour.

·Change in bowel habits including diarrhea or constipation or a change in the consistency of your stool.

·Patient will have the symptoms like Persistent abdominal pain such as cramps, or discomfort.

·Patient will be having a feel that the bowel movement has not completely emptied.

·Unexplained and unexpected weight loss

·Causes weakness or fatigue.

·Bowel obstruction.

Related Conference

 Oral, Mouth and Throat Cancer August 15-17, 2016 Portland, Oregon, USA. Cervical Cancer and Therapeutics August 04-05, 2016 Manchester, UK. Radiation Oncology November 21-22, 2016 Dubai, UAE. Multiple Myeloma conference Oct 15-17, 2017 Milano, Italy. Surgical Oncology October  03-05, 2016 Atlanta, Georgia, USA.2017.Annual Meeting of The Association of Coloproctology of Great Britain & Ireland 3rd July – 5th July 2017 Bournemouth International Centre,UK. AACR Colorectal Cancer: From Initiation to Outcomes September 17-20, 2016 Tampa, Florida. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. St Mark's 14th Annual International Congress: Frontiers In Intestinal And Colorectal Disease 2016 November 22, 2016 - November 25, 2016 Harrow , United Kingdom. Dilemmas & Debates In Colorectal Surgery 2016 November 8- 12, 2016 London , United Kingdom. 6th Enhanced Recovery After Surgery Society (U.k) Conference 2016 NOVEMBER 4, 2016 Cardiff , United Kingdom. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours  29-1 September,2016 Utrecht, Netherlands. 4th International Controversies in Rectal Cancer Conference 14th –15th  September 2016 Colchester, Essex, U.K.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 5: Colorectal Cancer: Diagnosis

A digital (finger) rectal examination is done to check the problems with organs or other structures in the pelvis and lower belly. A digital rectal exam (DRE) is done to find the cause of symptoms such as rectal bleeding, pelvic pain, a change in urination, or change in bowel habits Faecal occult blood can be a sign of a problem in your digestive system, such as growth, or polyp, or cancer in the colon or rectum. Sigmoidoscopy is a procedure which is used to see inside the sigmoid colon and rectum. The sigmoid colon is the area of large intestine nearest to the rectum Colonoscopy is a procedure which enables an examiner to evaluate the inside of the colon. The Colonoscope is a four foot long and flexible tube about the thickness of a finger with a camera and a source of light at its tip.

Related Conferences:

Surgical Oncology Conference October  03-05, 2016 Atlanta, Georgia, USA. 14th World Congress on Cancer Therapy December  05-07, 2016 Philadelphia, Pennsylvania, USA.13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE.Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. Spring Colorectal Meeting New Zealand September 14 - 17, 2016. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:  Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 6: Colorectal Cancer: Treatment

New therapeutic strategies with the established treatment regimens are most important and very much needed in pancreatic cancer it represents a novel approach to the management of pancreas cancer, so the pathological development of vascular supply is a major step for tumour growth and may affect its prognosis.

Epidermal growth factor receptors play an important role in controlling normal cell growth. Mutations of EGFRs can lead to continual or abnormal activation of the receptors causing unregulated cell division, which gives rise to some types of cancers these are the Current immunotherapies for colorectal cancer is categorized into different broad categories: they are:

1.    Monoclonal-antibodies,

2.    Checkpoint-inhibitors,

3.    Immune modulators,

4.    Cancer vaccines,

5.    Adoptive cell therapy,

6.    Cytokines and

7.    Adjuvant immunotherapies.

These therapies are still undergoing early-phase clinical testing (phase I and II) for colorectal cancer but their successful use in treating other types of cancers may ultimately prove useful for colorectal cancer, Oncology conferences and Global cancer conferences.

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Lymphoma July 24-26, 2017 Rome, Italy. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:  Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 7: Pancreatic & Colorectal Cancer: Therapeutics

Some of the drugs in the pipeline for colorectal cancer therapeutics are Lonsurf, CYRAMZA (ramucirumab), TS-1/Teysuno, CPP-1X (eflornithine hydrochloride), MelCancerVac, Xilonix, and Nintedanib. There are various medications such as chemotherapy drugs, immunotherapy, and leucovorin (chemoprotectant) that can be used to treat colorectal cancer. Chemotherapy drugs for the treatment of colorectal cancer include anti-metabolites such as fluorouracil and capecitabine. Monoclonal antibodies used in immunotherapy as part of the treatment of colorectal cancer are bevacizumab, cetuximab, and panitumumab. Bevacizumab (Avastin®), ramucirumab (Cyramza®), and ziv-aflibercept (Zaltrap®) are drugs used for colon cancer that target vascular endothelial growth factor (VEGF). VEGF is a protein that helps tumors form new blood vessels to get nutrients (a process known as angiogenesis).

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Lymphoma Conference July 24-26, 2017 Rome, Italy. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:  Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 8: Colorectal Cancer: Stages

Stage 0 Colorectal Cancer is found only in the innermost lining of the colon. Treatment usually involves local excision to remove the tumour and a small amount of surrounding tissue or to remove larger colon cancers. Stage I tumours have spread beyond the inner lining of the colon to the second and third layers and involves the inside wall of the colon. Stage II colorectal cancers are larger and extend through the muscular wall of the colon. For stage-III of colorectal cancer, surgical removal of the tumour is the initial treatment except for stage-IV   For some type of cancers, additional treatments, like adjuvant therapy may be recommended.

Related Conferences:

 Oral, Mouth and Throat Cancer August 15-17, 2016 Portland, Oregon, USA. Cervical Cancer and Therapeutics August 04-05, 2016 Manchester, UK. Radiation Oncology November 21-22, 2016 Dubai, UAE. Myeloma Conference Oct 15-17, 2017 Milano, Italy. Surgical Oncology October  03-05, 2016 Atlanta, Georgia, USA.2017. Annual Meeting of The Association of Coloproctology of Great Britain & Ireland 3rd July – 5th July 2017 Bournemouth International Centre,UK. AACR Colorectal Cancer: From Initiation to Outcomes September 17-20, 2016 Tampa, Florida. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. St Mark's 14th Annual International Congress: Frontiers In Intestinal And Colorectal Disease 2016 November 22, 2016 - November 25, 2016 Harrow , United Kingdom. Dilemmas & Debates In Colorectal Surgery 2016 November 8- 12, 2016 London , United Kingdom. 6th Enhanced Recovery After Surgery Society (U.k) Conference 2016 NOVEMBER 4, 2016 Cardiff , United Kingdom. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours  29-1 September,2016 Utrecht, Netherlands. 4th International Controversies in Rectal Cancer Conference 14th  – 15th  September 2016 Colchester, Essex, U.K.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

 

Track 9: Colorectal cancer: Pathogenesis

Sporadic (Nonhereditary) Colorectal Cancer is detected through screening procedures or when the patient presents with symptoms. Screening is important for prevention and should be a part of routine care for adults over the age of 50 who are at low-risk. High-risk individuals (those who are with previous colon cancer, those who have family history of colon cancer, and those who have inflammatory bowel disease or history of colorectal polyps) require careful follow-up. Major advances have been made in our understanding of molecular events leading to the formation of adenomatous polyps and cancer most of the colorectal cancers are sporadic.

Related Conferences:

2nd Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA. Lymphoma July 24-26, 2017 Rome, Italy. 13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia.14th World Congress on Cancer Therapy December 05-07, 2016 Philadelphia, Pennsylvania, USA.5th Radiology and Imaging September 19-20, 2016, Las Vegas, Nevada, USA. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours  29-1 September,2016 Utrecht, Netherlands. European Colorectal Congress 2016 November 29, 2016 - December 2, 2016,St.Gallen , Switzerland. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 10: Surgical & Non-Surgical Methods

 hemicolectomy is an operation used to remove a part of the large bowel (colon/intestine) because either it is not working properly or it is diseased. Sigmoid Colectomy is an operation used to a remove part of the left side of the colon known as the sigmoid colon. It may be performed for the patients with colon cancer or for non-cancerous conditions such as Crohn’s disease, diverticular disease or sometimes performed as a part of surgery for rectal prolapse. In most of the cases the operation can be performed via laparoscopic (keyhole) surgical technique. Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy can also be used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancers. Radiofrequency Ablation is an image-guided technique that heats and destroys cancer cells.

Related Conferences:

Radiation Oncology November 21-22, 2016 Dubai, UAE.
12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Lymphoma Conference July 24-26, 2017 Rome, Italy. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:  Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. Dilemmas & Debates In Colorectal Surgery 2016 November 8- 12, 2016 London , United Kingdom.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 11: Colorectal Cancer: Advancements

Single-port laparoscopic surgery (SPLS) for colorectal pathology is an advanced technique whereas laparoscopic surgery is carried out through a single small incision hidden in the umbilicus.

Da Vinci® surgical system is a robotic surgical system that was designed to compensate the limitations of both open and laparoscopic surgery. This surgical system consists of three separate components. The first is the surgeon's console where the surgeon sits. The second component is the cart with four robotic arms and the third is an electronic tower holding video and air inflation equipment. Surgeon performs the surgery by manipulating the robotic controls in the console. A cart is the robot which performs the operation according to the signals from the first component. Thus, the robot in da Vinci® surgical system is a slave robot. It has no ability and no intelligence to perform the operation by itself. A binocular camera system is attached through the laparoscopic port for insertion and provides three-dimensional images to the surgeon.

 

 

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 7th International Conference and Expo on Molecular & Cancer Biomarkers, September 15-16, 2016 Berlin, Germany. Conference on Lymphoma July 24-26, 2017 Rome, Italy. 58th ASH Annual Meeting & Exposition, Dec 2016 California, USA, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:  Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8, 2016 - December 10, 2016 Orlando , United States.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 12: Pancreatic Cancer: Novel Approaches

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and devastating disease, which is characterized by invasiveness and dissemination to the lymphatic system and distant organs. In the absence of effective screening methods considerable efforts have thus been made to identify better systemic treatments than gemcitabine, the standard of care for advanced PDAC for well over a decade.

PDAC is an extraordinarily lethal disease, which, despite a more or less efficient chemotherapeutic treatment, systematically displays a rapid and uncontrolled progression towards a fatal recurrence. Determining which cells give rise to such tumour recurrence is thus crucial before an improved therapeutics outcome can be envisaged for patients with PDAC.

RelatedConferences:

RadiationOncologyNovember21-22,2016Dubai,UAE.12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. 2nd World Congress and Exhibition on Antibiotics and Antibiotic Resistance. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress, 29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology 4-6 November 2016 Lausanne, Switzerland. Dilemmas & Debates In Colorectal Surgery 2016 November 8- 12, 2016 London , United Kingdom.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 13: Colorectal Cancer: Practice

Early detection of pancreatic cancer is unfortunately an infrequent situation at the present time. Consequently, there are no current screening programmes that can be recommended in the general population. However, some patients are at greater risk of developing a pancreatic cancer. The risk of pancreatic cancer is increased significantly (18-fold) in families with an affected first-degree relative. Pancreatic cancer is associated with several genetic syndromes including hereditary pancreatitis syndrome, hereditary non-polyposis colorectal cancer, hereditary atypical multiple mole melanoma syndrome, hereditary BRCA2-related breast and ovarian cancer and Peutz–Jeghers syndrome. For these patients specific programs have been established in order to recognize pre-cancerous lesions.

Related Conferences:

5th Radiology and Imaging September 19-20, 2016, Las Vegas, Nevada, USA. Surgical Oncology October  03-05, 2016 Atlanta, Georgia, USA. 2nd Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Paediatric Academic Society Conference, May 6–9, 2017, California, USA, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours  29-1 September,2016 Utrecht, Netherlands. Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 14: Colorectal Cancer: Prevention

While no cancer is completely preventable so it is estimated that changes in diet and physical activities could reduce the incidence of bowel cancer by up to 75%. Consumption of foods containing dietary fiber protect against bowel cancer.

A combination of drugs often works better than a single drug in treating colorectal cancer. The most commonly used drugs are:  Fluorouracil (5-FU) combined with leucovorin, Oxaliplatin, Capecitabine, Irinotecan. Colorectal cancer can often be prevented through regular screening, which can find precancerous polyps because colorectal cancer generally does not cause symptoms until the disease is advanced, it is much important for people to talk with their doctor about the pros and cons of each screening test and how often each test should be given. Hopefully, this will lower the number of deaths caused by cancer.

Related Conferences:

12th Cancer Science Events Europe September 26-28, 2016 London, UK .12th World Cancer Conference September 26-28, 2016 London, UK.2nd Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA . Neuroendocrine Cancer Conference, Nov 7-9, 2016 Las Vegas, USA.  International Conference on Internal Medicine, November 03-05, 2016 USA. International Society Of University Colon And Rectal Surgeons (ISUCRS 2016) Mumbai, India,23rd - 25th September 2016. AACR International Conference on New Frontiers in Cancer Research, January 18-22, 2017 Cape Town, South Africa ; American Society of Clinical Oncology 2017 Annual Meeting, June 02-06, 2017 Chicago, United States 8th European Multidisciplinary Colorectal Cancer Congress 11 - 13 december 2016 RAI Amsterdam Netharland.15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours  29-1 September,2016 Utrecht, Netherlands. European Colorectal Congress 2016 November 29, 2016 - December 2, 2016,St.Gallen , Switzerland. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States. 4th International Controversies in Rectal Cancer Conference 14th September – 15th September 2016 ICENI Centre Colchester Hospital, Colchester, Essex C04 5JL U.K.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

 

Track 15: Colorectal Cancer: Oncologists

Gastro-intestinal oncologist is a physician who specializes in the diagnosis and treatment of the people with cancer of the gastro-intestinal organs. Specifically, the gastro-intestinal oncologist treats cancer of the colon, pancreas, rectum, small intestine, gall bladder, and other gastric cancers. If chemotherapy is indicated, the same gastro-intestinal oncologist is capable of administering treatment.

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Lymphoma Conference July 24-26, 2017 Rome, Italy. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington ,United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:  Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016.  Worldwide Cancer Events November 21-23, 2016 Dubai, UAE.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 16:  Colorectal Cancer: Case Reports

Pancreatic and Colorectal Cancer case reports  play a crucial role in moving new treatments to patients who need them most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Oncology Esthetics is the practice of safe and beneficial spa services by individuals trained to understand how colorectal cancer and associated medical treatments affect the body. Pancreatic and Colorectal Oncology Nutrition includes the current therapies used to treat the cancer and nutrition related side effects. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients. If a patient with colorectal carcinoma develops metastatic disease of musculoskeletal oncology, the bone lesion may become dense and hard. There are currently more than several Phase III drug trials and more than 90 Phase I/II trials in process for colorectal cancer sin USA and Germany.

Related Conferences:

2nd Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA. Lymphoma Conference July 24-26, 2017 Rome, Italy. 13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia.14th World Cancer Therapy December 05-07, 2016 Philadelphia, Pennsylvania, USA.5th Radiology and Imaging September 19-20, 2016, Las Vegas, Nevada, USA. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours  29-1 September,2016 Utrecht, Netherlands. European Colorectal Congress 2016 November 29, 2016 - December 2, 2016,St.Gallen , Switzerland. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States.

12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

 

 

OMICS International cordially invites all the participants across the globe to attend the “International conference on Gastrointestinal Cancer and Therapeutics” September 26-27, 2016 at Toronto, Canada.

GI cancer 2016 will mainly focus on the advancements in the treatment of Gastrointestinal cancer and also addresses the recent developments in the surgical oncology of gastrointestinal cancer. This will be a most prominent global cancer conference where the eminent personalities dealing with the current research works on oncology and specialists in treatment of different types of cancers will discuss and create awareness on risk factors management of cancer. This cancer meeting also discuss the practical challenges encountered and the possible key solutions that can be adopted for treating Gastrointestinal Cancer.

Gastrointestinal cancer is the 3rd most commonly diagnosed cancer in Canada (excluding non-melanoma skin cancers). It is the 2nd leading cause of death from cancer in men and the 3rd leading cause of death from cancer in women in Canada. It is estimated that in 2015 that 25,100 Canadians will be diagnosed with gastrointestinal cancer. This represents 13% of all new cancer cases in 2015.9,300 Canadians will die from gastrointestinal cancer. This represents 12% of all cancer deaths in 2015.14,000 men will be diagnosed with colorectal cancer and 5,100 will die from it.11,100 women will be diagnosed with gastrointestinal cancer and 4,200 will die from it. On average, 69 Canadians will be diagnosed with gastrointestinal cancer every day. On average, 25 Canadians will die from gastrointestinal cancer every day. In both men and women, gastrointestinal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death and the second leading cause when both sexes are combined.

OMICS International is a pioneer and leading scientific event organizer, publishing around 700+ Open access journals and conducting over 500 Scientific Meetings all over the globe annually with the support of more than 1000 scientific associations, 80,000 editorial board members, and 7.5 million followers to its credit.  OMICS International hosts numerous Cancer ConferencesCancer meetingglobal cancer conferenceEuropean Oncology ConferencesSurgical oncology like skin cancer conference, colorectal cancer conference, breast cancer conference, liver cancer conference, lung cancer meetings, and Oncology Conferences where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions and which helps get possibilities for treating the diseases with new era, technology and research.

Why to attend?
With members from around the world focused on learning about Gastrointestinal Cancer, this is your best opportunity to reach the largest assemblage of participants from the Gastrointestinal Cancer community, Oncologists communityoncology societyEuropean oncology conferencesAmerican oncology societyCanadian Cancer society. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with advanced treatments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Gastrointestinal Cancer are the hallmarks of this conference.

 

Target Audience

  • Scientists
  • Students
  • Cancer Researchers
  • Faculty
  • Gastrointestinal Cancer Associations and Societies
  • Pancreatic Cancer Associations and Societies
  • Colon Cancer Associations and Societies
  • Rectal Cancer Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Biomedical Companies
  • Medical Devices Companies

Summary:

Colorectal cancer is a word used for cancer that starts in the colon or the rectum. These cancers can also be referred separately as colon cancer or rectal cancer, depending upon where they start. Colon cancer and the rectal cancer have many characters in common. Most of the colorectal cancers develop slowly over several years. Before the development of a cancer, a growth of tissue or tumour generally begins as a non-cancerous polyp on the inner lining of the colon or rectum. A tumour is an abnormal tissue and can be benign (not cancer) or malignant (cancer). A polyp is a benign and non-cancerous tumour. Some polyps can change into cancer but not all the polyps do. The chance of changing a polyp into a cancer depends on the kind of polyp

Colorectal cancer is the 3rd most commonly diagnosed cancer in Canada (excluding non-melanoma skin cancers). It is the 2nd leading cause of death from cancer in men and the 3rd leading cause of death from cancer in women in Canada.

Incidence is the total number of new cases of cancer. Mortality is the number of deaths due to cancer.

It is estimated that in 2015:

  • 25,100 Canadians will be diagnosed with colorectal cancer. This represents 13% of all new cancer cases in 2015.
  • 9,300 Canadians will die from colorectal cancer. This represents 12% of all cancer deaths in 2015.
  • 14,000 men will be diagnosed with colorectal cancer and 5,100 will die from it.
  • 11,100 women will be diagnosed with colorectal cancer and 4,200 will die from it.
  • On average, 69 Canadians will be diagnosed with colorectal cancer every day.
  • On average, 25 Canadians will die from colorectal cancer every day.

The death rate (the number of deaths per 100,000 people per year) because of the colorectal cancer has been reducing in both men and women for more than 20 years. There are many comparable reasons for this. One is those polyps are found by screening and removed before they develop into cancers. Screening allows more colorectal cancers to be found earlier when the disease is easier to cure. In addition, the treatment for colorectal cancer has improved from the last several years. Therefore, there are more than 1 million survivors of colorectal cancer in the United States.

Survival rates are often used by doctors as a typical way of discussing a person's prognosis. The 5-year observed survival rate mentions to the percentage of patients who live at least 5 years after their cancer is diagnosed. Certainly, many people live much longer than 5 years and many are cured.

Relative survival rates, like those in the table, compare the observed survival rate with what would be expected for people without the cancer. This helps to prevent the deaths caused by something besides cancer and is a better way to see the effect that the cancer has on survival.

In order to get survival rates of five years, doctors have to look at the people who were treated years ago and the Improvements in treatment so that it may result in more favourable outlook for people now being diagnosed with colorectal cancer.

Survival rates are often based on previous outcomes of large number of people who had the disease, but they were unable to predict what will happen in any of the particular person's case. Knowing the form and the phase of a person's cancer is important in estimating their outlook. But many other causes can also affect a person's outlook, such as the position of the cancer, the genetic variations in the cancer cells, the treatment received, and how the cancer responds to treatment. Even when we take these factors into consideration survival rates are at best coarse estimates.

Survival rates for colon cancer, by stage:

The numbers below come from the National Cancer Institute's SEER database, looking at people diagnosed with colon cancer between 2004 and 2010.

                                                                                Figure: 1

*These numbers are correct: patients with stage IIIA or IIIB cancers have better survival than those with stage IIB cancers.

These statistics are based on a previous version of the staging system. In that version, there was no stage IIC (those cancers were grouped considered stage IIB). Also, some cancers that are now considered stage IIIC were classified as stage IIIB, while some other cancers that are now considered stage IIIB were classified as stage IIIC.

Survival rates for rectal cancer, by stage:

The numbers below come from the National Cancer Institute's SEER database, looking at people diagnosed with rectal cancer between 2004 and 2010.

*These numbers are correct; survival was better for some stage III cancers than for some stage II cancers.

These statistics are based on a previous version of the staging system. In that version, there was no stage IIC (those cancers were considered stage IIB). Also, some cancers that are now considered stage IIIC were classified as stage IIIB, while some other cancers that are now considered stage IIIB were classified as stage IIIC.

                                                                                    Figure: 2

 

Scope and Importance of Colorectal Cancer Research:

Regular colorectal cancer screening or testing is one of the most powerful weapons for preventing colorectal cancer. The regularity rate of colorectal cancer has been falling for about the last 20 years. This is expected to be in large part due to screening (looking for cancer in people who have no symptoms of the disease). The diagnosis of colorectal tests can also find polyps, which will be able to be removed before they develop into cancers. The Research of Colorectal cancer involves the study of specific genetic alterations which are associated with the development and progress of colorectal cancer. By aiming on a specific area of the chromosome associated with colon cancer, called 20-q, we can detect 10 possible candidate genes that could potentially play significant roles in colon cancer. Some of these findings may lead to new approaches in the treatment of colorectal cancer.

 By assessing Avastin, a growth inhibitor in cancer cells, it led to the first clinical translational study which evaluates its efficacy on colon cancer patients. In addition, EIF funding was used to help establish the community-based Clinical Cancer Research Network at UCLA, which provides critically important systems to translate new and innovative ideas into clinical testing. Evaluating the role of prostaglandins such as PGE2, a signalling molecule produced by cancer cells in very high levels, and identified several new genes regulated by it.  One of those genes is called NR4A2, which has been shown to be instrumental in controlling cancer cell death. Another newly identified gene called GRO alpha was shown to inhibit colorectal tumour growth upon activation. These findings could be potentially important clinically because antibodies directed against these genes may be useful for the treatment of patients with colorectal cancer. According to the scientists, carrying out this kind of experiment is very high risk and would not be supported by other funding mechanisms. Thus, the support from EIF has been crucial.  Increased levels of folic acids and vitamin-D are two of the most promising factors which could prevent colon cancer. Other factors include, being physically active and fit, avoid smoking, and reduce red meat consumption. Researchers have developed a test that can find areas of colon cancer spread in nearby lymph nodes that wouldn’t have been found with the test normally used. By recognizing a kind of RNA that is found in colon cancer but not in normal lymph node cells, this may help identify patients who have a higher stage of colon cancer than originally suspected, and who might benefit from chemotherapy after surgery.

Much of our understanding of the fundamental genetic and molecular biological processes driving colorectal cancer pathogenesis has come from studies of somatic mutations in sporadic, non-inherited colorectal cancers and germ line mutations in familial and inherited colorectal cancers. The current genetic-based paradigm of colorectal tumourogenesis as described by Vogelstein et al. is partially based on molecular analysis of sporadic primary colorectal cancer in which compounding genetic mutations lead to the transformation of a benign polyp into invasive colorectal cancer. Studies of germ line mutations found in inherited forms of colorectal cancer, such as familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (HNPCC), also helped to shed light on additional genes involved in malignant transformation. One by one, tumour suppressor genes, DNA mismatch repair genes and proto-oncogenes have been identified and their roles elucidated in the progression from normal colonic epithelium to carcinoma.

With the advent of next-generation sequencing (NGS) technology and its associated massive output in DNA sequence, the newfound ability to re-sequence individual cancer genomes opens a new chapter in biomedical cancer research with the potential for future tailoring of medical care. In this article, we will first discuss the current methods for prognosticating and predicting response to chemotherapy in colorectal cancer with a focus on current genetic-based biomarkers. We will then examine the advances in NGS technology and discuss their application to future colorectal cancer research and clinical practice.

Why it’s in Toronto, Canada?

Toronto, the provincial capital of Ontario, Canada, is a large, ethnically diverse city sprawling along Lake Ontario’s north-western shore. Toronto is positioned in the middle of the newly formed Québec-Ontario Life Sciences Corridor - the second largest life sciences cluster in North America. The Corridor plays a major role in the advancement of life sciences discovery and its related commercialization.

Toronto is a leading international centre of business, finance, arts, and culture, and is widely recognized as one of the most multicultural and cosmopolitan cities in the world. The Toronto/Ontario biotech cluster is the largest in Canada with 163 companies. Nearly 50 global pharmaceutical and biotechnology companies have their Canadian headquarters in the Toronto region. Toronto’s Discovery District is a centre of research in biomedicine, It is also home to the Medical and Related Sciences Centre which was created in 2000 to capitalize on the research and innovation strength of the Province of Ontario, There are over forty hospitals located in the City of Toronto. Many of them are also medical research facilities .Princess Margaret Cancer Centre is one of the Top 5 Cancer Research Centres in the World which is located in Toronto. A dynamic metropolis with a core of soaring skyscrapers, all dwarfed by the iconic CN Tower, it also features abundant green spaces, from the orderly oval of Queen’s Park to 400-acre High Park and its trails, sports facilities and zoo.

Toronto is the leading tourism destination in Canada, attracting more than 25 million Canadian, American and international visitors annually (Tourism Toronto, 2012). In 2012, the Toronto region welcomed 9.9 million overnight visitors. Visitors to Toronto spend about $5.1 billion in direct expenditures during their visits. Visitors to the Toronto region support more than 329,000 people who work in tourism and hospitality. Based on 2013 estimates, Toronto welcomed 13.69 million overnight visitors. 1.42 million visitors arrived from overseas markets (all countries other than Canada and the U.S.)

 Members associated with Colorectal Cancer Research:

 There are Oncologists, Doctors, scientists, researchers, colorectal cancer specialists, professors, Ph.D. professionals, surgeons, gastroenterologists who are associated with the colorectal cancer research. Among the city Toronto there are about 1764 members and among Canada there are about 9000 and in the world there are about 17000 members are associated with the colorectal cancer research.

Hospitals Associated with Colorectal Cancer Research:

It was found that there are about 238 hospitals in Toronto, Ontario which are associated with colorectal cancer research and there are 1,387 hospitals approximately in Canada and there are more than 10000 hospitals all over the world which are associated with colorectal cancer research.

Some of the Hospitals in Toronto, Ontario and Canada:

Princess Margaret Cancer Centre   
St. Michael's Hospital is in downtown Toronto

Cancer Care Ontario

The Ottawa Hospital Cancer Centre

Toronto Western Hospital

Windsor Regional Cancer Program

Odette Cancer Centre

Simcoe Muskoka Regional Cancer Centre

Sunny Brook Health science Centre

London Regional Cancer Program

Grand River Regional Cancer Centre

Juravinski Cancer Centre

Carlo Fidani Peel Regional Cancer Centre

Stronach Regional Cancer Centre at Southlake

R.S. McLaughlin Durham Regional Cancer Centre

Mount Sinai Hospital

Cancer Centre of Southeastern Ontario

Northeast Cancer Centre

Regional Cancer Care – Northwest

St. Joseph’s Health Centre

Renascent Treatment Centres

Agulefo, N T C MD

Societies Associated with Colorectal Cancer Research:

There are almost 205 societies in Toronto and 785 societies in Canada and there are approximately 5786 societies which are dealing with the colorectal cancer Research. Some of the societies are:

Colorectal Cancer Association of Canada - CCAC

National Pancreatic Cancer Canada Foundation

Canadian Cancer Society

Ontario - Canadian Cancer Society

The Ewings Cancer Foundation of Canada

Colon Cancer Canada

Colon and rectum cancer - CRS

CURE Childhood Cancer Association

Canadian Diabetes Association

Canadian Association of Gastroenterology

Gastrointestinal Society

Canadian College of Health Service Executives – CCHSE

Canadian Medical Association

Association of obesity and cancer risk in Canada

Canadian Public Health Association

National Association of County and City Health Officials (NACCHO)

Ontario Medical Association

Canadian Association of Occupational Therapists

Health & Wellness Foundation

Industries Associated with Colorectal Cancer Research:

  There are 328 Industries in Toronto and 1200 industries in Canada and about 5200 industries all over the world which are associated with colorectal cancer research. Some of the major Industries which are dealing with the manufacturing of drugs for colorectal cancer therapy are listed below:

Novartis Pharmaceuticals Canada

Johnson & Johnson Canada

Pfizer Pharmaceuticals Canada

Mylan

Merck Pharmaceuticals

Actavis Pharma Company

Bayer Pharmaceuticals

GlaxoSmithKline pharmaceuticals Canada

Apotex Inc.

Pharmascience Inc.

Teva Canada

Del Mar Pharmaceuticals

Algorithme Pharma

Anavex Life Sciences

Concordia Healthcare

Enox Biopharma

Nordion

Tekmira Pharmaceuticals

Universities Associated with Colorectal Cancer Research:

A total of 175 Universities were found in Toronto and there are 595 universities in Canada and there are around 5000 universities all over the world.

Some of the universities are:

University of Toronto

McGill University

University of British Columbia (UBC)

Canadian universities

The University of Western Ontario

McMaster University

University of Calgary

University of Manitoba College of Medicine

Memorial University of Newfoundland

University of Ottawa

Queen’s School of Medicine

 Toronto School of Medicine

Trinity Medical College

Victoria University Medical Department

Memorial University of Newfoundland Faculty of Medicine

University of Bishop College Faculty of Medicine

Laval University

Dalhousie University 

Northern Ontario School of Medicine

Royal College of Physicians and Surgeons

Market Value on Colorectal Cancer Research:

The global in-vitro colorectal cancer screening tests market was valued at USD 559.3 million in 2014 and is likely to grow at a CAGR of 5.2% over the forecast period. Growing incidences of colon and rectal cancer and the introduction of novel screening tests employing genetic testing are the major factors expected to drive the in-vitro colorectal cancer screening tests market over the forecast period. The introduction of government regulations aimed at mandatory application of cancer screening tests, growing demand for novel minimally invasive tests which screen for colorectal cancer using DNA and genetic biomarkers and the increasing prevalence of colorectal cancer are expected to fuel the growth of the market for in-vitro colorectal cancer screening tests. Globally, colorectal cancer (CRC) is the third most prevalent form of cancer. CRC accounts for almost a tenth of all cancer incidences worldwide. This incidence has only been increasing over the last couple of years. Furthermore, the introduction of novel colorectal tests which use biomarkers such as tumour M2-PK marker or which screen for colorectal cancer using methylated genes for screening will witness a growth in market demand throughout the forecast period. The primary factor responsible for this shift in trend can be attributed to by the increased accuracy of screening which these newer genetic tests have to offer. Its market is expected to reach an estimated value of over USD 250.0 million by 2020. According to a report published by W.H.O cancer fatalities are expected to increase from 14 million in 2012 to 22 million in 2020.

This report provides annualized colorectal cancer therapeutics market revenue, cost of therapy, and treatment usage patterns across eight major markets, namely the US, France, Germany, Italy, Spain, UK, Japan and China, from 2013 and forecast to 2023. Key topics covered include pipeline analysis, strategic competitor assessment, unmet needs, remaining commercial opportunities, and current and future players.

Market Growth of Colorectal Cancer Research in the last and upcoming ten years:

Colorectal Cancer (CRC) research market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.    

Fund Allotment to Colorectal Cancer Research:

The fund allotment for the colorectal cancer research in Toronto is about $2,95,91,500 and in Canada it is about $5,97,22,400 and all over the  world it is about $8,88,97,055.                                                                                     

No. of  Physicians, Researchers and Academicians:

There are about 10795 physicians, 2497 Researchers and about 19585 Academicians in Canada and about 34000 physicians, 10951 Researchers and about 55725 Academicians all over the world.

References:

http://www.prnewswire.com/news-releases/colorectal-cancer-treatment-market-value-to-exceed-9-billion-by-2020-508116511.html

http://www.drug-dev.com/Main/Back-Issues/Colorectal-Cancer-Treatment-Market-Value-to-Hit-94-846.aspx

http://www.reuters.com/article/2015/03/23/research-and-markets-idUSnBw235511a+100+BSW20150323

http://www.pharmaasia.com/article/apac-colorectal-cancer-therapeutics-market-value-to-reach-us-3b-by-2020/11177

http://www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market

http://www.grandviewresearch.com/industry-analysis/super-resolution-microscopes-industry

https://www.pancan.org/wp-content/uploads/2013/01/incidence_report_2012.pdf

http://cancer.dartmouth.edu/support_services/documents/cancer_websites_april2011.pdf

http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/

http://chemoth.com/economics

http://www.cancerindex.org/clinks7.htm

http://www.ccalliance.org/

Cancer Science-2014

OMICS International hosted 4th World Congress on Cancer Therapy during October 20-22, 2014 at Park Regis Chicago, USA with the theme “Enhanced diagnosis, treatment and management of different cancers". The conference had multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from various scientists, researchers, students and leaders from the field of oncology who made this event successful. The conference was initiated with a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list includes:

Jeffrey B Ulmer ( University of Regina), Dr. Sudhakar Akul Yakkanti(Stanford Research Institute (SRI) International, Menlo Park, California), Reza Hakkak(Professor of Pediatrics in the College of Medicine), OMICS International thank all our expert presenters from all around the world which includes various outside experts, University representatives and other eminent researchers who supported the conference by facilitating the discussion forums.

 

Past Reports  Gallery  

Cancer Science-2013

The 3rd World Congress on Cancer Science & Therapy was organized by OMICS Group Inc., during October 21-23, 2013 at Double Tree by Hilton Hotel San Francisco Airport, USA. The conference was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who have driven this event into the path of success. The conference had multiple sessions, Keynote presentations, panel discussions and Poster sessions. Dr. Jimmy T. Efird, Brody School of Medicine, USA Was honorable Moderator for the conference. The conference proceedings were carried out through various Keynote-presentations by: Dr. Stewart Sell, Wadsworth Center, USA, Dr. Michael Retsky, Harvard School of Public Health, USA, Dr. Jimmy T. Efird, Brody School of Medicine, USA and the wonderful workshop session was organized by Dr. Dorothee Herlyn, The Wistar Institute, USA.


Past Reports  Gallery  

Cancer Science-2012

OMICS International 2nd World Congress on Cancer Science & Therapy was held during September 10-12, 2012 at Hilton San Antonio Airport, San Antonio, USA.
The conference proceedings were carried out through effectual keynote lectures by:Dr. Sudhakar Akul Yakkanti, Boys Town National Research Hospital, USA,Dr. Alexei G. Basnakian, University of Arkansas for Medical Sciences, USA,Dr. Dan Dixon, University of South Carolina, USA,Dr. Sophia Ran, Southern Illinois University School of Medicine, USA, Dr. Homer S Black, Baylor College of Medicine, USA

We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance towards the success of Cancer Science-2012. With the unique feedback from the conference.


Past Reports  Gallery  

Cancer Science-2011

The International Conference and Exhibition on Cancer Science and Therapy (Cancer Science-2011), hosted by the OMICS Group was held on August 15-17, 2011 in Las Vegas, USA. It attracted around 350 delegates from across the cancer science community of the world for a day of lively discussion and debate. The conference focused on the Novel approaches in cancer science & therapy

We are particularly grateful to our conference chairs and Key note speakers: Dr. Mahin Khatami, National Cancer Institute, USA,Dr. Michael MIngzhao Xing, Johns Hopkins University School of Medicine, USA,Dr. Francois Vallete, INSERM and Universite de Nantes, France,Dr. Stephen Wang, Millennium Pharmaceuticals Inc, USA,Dr. Jimmy Efird, Brody School of Medicine, USA,Dr. John Thompson, University of Waterloo, Canada. 

We are also grateful to other speakers and Senesco Technologies Inc., USA who supported the conference by facilitating the discussion forums. As part of a collaborative effort, Journal of Cancer Science & Therapy and Journal of Carcinogenesis & Mutagenesis has published all papers presented at this meeting as a special issue.Cancer science 2011 witnessed a success in great magnitude event. 


Past Reports  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date September 26-27, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2
Poster Opportunity Available

Conferenceseries Destinations